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Little scientiﬁc evidence supports the eﬃcacy of herbal medicines in the treatment of women with sleep diﬃculty during the
climacteric period. The purpose of this study is to evaluate the eﬃcacy and safety of Suan Zao Ren Tang (SZRT) in reducing the
impact of sleep disturbance on climacteric women, as measured by Pittsburg sleep quality index (PSQI) and the World Health
Organization quality of life (WHOQOL). Sixty-seven climacteric women with sleep diﬃculty intending to treat received SZRT
at a rate of 4.0g, thrice daily for four weeks (MRS < 16, n = 34; MRS ≥ 16, n = 33). After taking into account potential
confounding factors, the mean PSQI total scores had fallen from 13.0 (±2.9) to 9.0 (±3.2) (95% conﬁdence interval −4.93,
−3.10). Further analyses showed that SZRT produced superior beneﬁt of daytime dysfunction in women with severe menopausal
symptoms (MRS ≥ 16). There were three of the withdrawals involved treatment-related adverse events (stomachache, diarrhea,
and dizziness). Excluding women with a past history of stomachache, diarrhea, or dizziness, four weeks of therapy with SZRT
appears to be a relatively safe and eﬀective short-term therapeutic option in improving daytime function of climacteric women
with poor sleep quality.
1.Introduction
Insomnia is not only one of the most common symptoms of
menopause [1–4], but also one of the major determinants
relating to quality of life (QOL) for climacteric women
seeking medical advice [5]. This condition occurs in over
50% of climacteric women and could act, in an independent
or synergistic way, with various menopausal symptoms to
impact their daytime function [5, 6]. For treating insomnia,
benzodiazepines quickly gained acceptance as the preferred
treatment after a debut on the pharmaceutical market in
1960. Despite clinical guidelines recommending their use
[7], there are still claims that the beneﬁts of taking this
oldergenerationofhypnoticsareoutweighedbyseriousrisks
including daytime sedation, dependence, rebound insomnia,
slurred speech, staggering gait, poor judgment, and slow
uncertain reﬂexes. Not surprisingly, many women with sleep
diﬃculty have turned to traditional medicine in search of a
way to manage their sleep problems and promote their QOL.
Suan Zao Ren Tang (SZRT)h a sal o n gh i s t o r yo fu s ea s
part of the traditional Chinese pharmacopoeia ﬁrst docume-
nted in the classical Chinese text Jin Gui Yao Lue (Essential
Prescriptions from the Golden Cabinet) circa 210 A.D. by
Zhong-Jing Zhang [8]. SZRT is a combination of ﬁve medic-
inal Chinese herbs as follows: Semen Zizyphi Spinosae (Suan-
zaoren), Sclerotium Poriae Cocos (Fuling), Radix Ligustici
Chuanxiong (Chuanxiong), Rhizoma Anemarrhena (Zhimu),
and Radix Glycyrrhizae (Gancao)[ 9]( Table 1). In the
classical literature, SZRT is said to nourish the blood
and calm the nerves to eventually bring on a tranquilliz-
ing sensation and reduce the eﬀect of sleep disturbance.
Traditional medicine (TM) practitioners in Japan, South
Korea, China, and Taiwan, which have a similar history of
traditional Chinese medicine (TCM), rely on the indications
and contraindications mentioned in the thousand-year-old
classical literature of Chinese medicine.
Our previous study demonstrated that SZRT is fre-
quentlyprescribedforclimactericwomeninTaiwan[10,11].
In the United States, SZRT is also available, but as an over-
the-counterdietarysupplement.Despiteitspopularity,SZRT
does not have any scientiﬁc evidence to back up claims of
eﬃcacy or safety in clinical use. Pharmaceutical companies2 Evidence-Based Complementary and Alternative Medicine
Table 1: Nomenclature of Chinese herbs in Suan Zao Ren Tang.
Pharmaceutical
name Chinese Pinyin Latin botanical name
Semen Zizyphi
Spinosae Suanzaoren Ziziphus jujuba var.
Spinosa
Sclerotium Poriae
Cocos Fuling Poria cocos (Schw.)
Wolf
Radix Ligustici
Chuanxiong Chuanxiong Ligusticum chuanxiong
Hort.
Rhizoma
Anemarrhena Zhimu Anemarrhena
aspodeloidea Bunge
Radix Glycyrrhizae Gancao Glycyrrhiza uralensis
Fisch.
aregenerallyreluctanttoconductanyrandomizedcontrolled
trial for SZRT that is already on the market and approved
by regulatory bodies. However, it is unethical not to conduct
clinical trials to outline the safety proﬁle of SZRT; clinical
trials will also provide basic knowledge to explore SZRT’s
possible mechanisms of eﬀectiveness. Therefore, an observa-
tion period of four weeks can start to expose any unknown
side eﬀects and may verify an ancient indication that SZRT
is eﬀective in improving sleep quality, sleep latency, sleep
disturbance, sleep eﬃciency, and daytime function during
theclimactericperiod,acomplexstageinthelifeofawoman.
2. Methods
2.1. Herbal Formula. The SZRT formula used in this study is
aherbalextractpowderfromthegoodmanufacturingproce-
dures(GMP)ofthecertiﬁedcompanyKaiserPharmaceutical
Co., Ltd. (Taiwan), for the purpose of meeting international
market standards of quality and uniformity. The project was
entirely funded by the Taipei Chinese Medical Association
to detect potential toxicity or AEs of SZRT.A p a r tf r o m
providing the batch of SZRT, Kaiser Pharmaceutical was
not involved in any other sponsorship, study design, or
monitoring of the participants.
2.2. Preparation of the Herbs. All herbal components of
SZRT were prepared in a large computer-controlled boiler
where volatile oils and herbal broth were collected, pumped
into a vacuum drying condenser, and sprayed onto a base
material. These granulated compounds were then vacuum-
dried at low temperatures before being siphoned into a
separate sterile-room, where they were bottled, labeled, and
s e a l e d .G r a n u l e sw e r ep a c k e di na l u m i n u mf o i lp a c k a g e sa n d
administered orally at a dose of 4g, three times per day. For
quality assurance of the active ingredients in SZRT,H P L C
(high performance liquid chromatography) ﬁngerprinting
was employed to identify substances in the ﬁnal product.
No animal products, endangered species, or restricted herbal
ingredients were used in this study. Each batch of SZRT was
also tested for E. coli, Salmonella (bacteria count), and heavy
metals.
2.3. Recruitment of Subjects. The Yang Ming branch of the
Taipei City Hospital was the location for patient enrollment
in the study. The study obtained approval from the Taipei
City Hospital Institutional Review Board (TCHIRB-970110-
E). Participants were recruited through newspaper advertise-
ments and ﬂyers posted in clinics and health fairs between
April 2008 and April 2010. All participants understood the
nature of the trial and willingly signed the informed consent
form.
2.4. Eligibility Criteria. The subjects enrolled in the study
were climacteric women, ranging from 40–65 years of age,
with a Pittsburg sleep quality index (PSQI) of greater than
six. These women spent 45 minutes or more falling asleep,
slept less than six hours, and had struggled with this issue
continuously for at least one month.
2.5. Ineligibility Criteria. The reasons women were unable
to participate in the study were as follows: (1) within three
months of the study there had been a major incident,
(2) working the nightshift, (3) lack of time or timing
conﬂicts, (4) confounding diseases such as psychosis, severe
depression, obstructive sleep apnea-hypopnea, restless legs
syndrome, cardiac arrhythmia, acute myocardial infarction,
high blood pressure, diabetes, or cancer, (5) currently
taking pharmaceuticals that aﬀect melatonin, acetylcholine,
glutamate, serotonin, norepinephrine, GABA, histamine,
adenosine, or prostaglandins, (6) inability to read and ﬁll
out the forms for the study, and (7) any evidence of renal
or liver dysfunction as deﬁned by a level of at least 1.5 times
of the upper reference limit (serum creatinine: 1.3mg/dL,
blood urea nitrogen (BUN): 22mg/dL, serum aspartate-
aminotransferase (AST): 25IU/L, alanine-aminotransferase
(ALT): 29IU/L).
2.6. Study Design and Procedure. Nurses were briefed on
important items prior to the start of the study and attended
a training session to ensure duties were conducted in
accordance with good clinical practice (GCP) guidelines.
Participants passed through an initial screening phase of two
visits. On the ﬁrst visit, they were interviewed to obtain
information about medical history and were later subjected
to a clinical examination. The second visit determined the
baseline data on symptoms, quality of life, and a basic
health assessment that consisted of complete blood counts
and biochemical function tests. These tests were performed
to ensure the eligibility of each woman and to identify
respondents with potential poor compliance. At the end of
the second visit, each eligible woman was provided with
suﬃcient SZRT at a treatment dose of 4g thrice daily to take
untilthenextvisit.Andnootherherbalswereallowedduring
the study period.
Followup visits were scheduled for the ﬁrst and fourth
weeks of the study. Physical examinations, basic health
assessments, and biochemical function tests for each womanEvidence-Based Complementary and Alternative Medicine 3
werecarriedoutattheendofthestudy.Attheendofthetrial,
the participants received a further physical examination,
including blood tests. Women were contacted by telephone
one to two days prior to each visit to encourage their con-
tinued participation. Throughout the study, leftover package
counts were done to monitor each woman’s compliance. The
occurrence of AEs was recorded on every visit.
2.7. Eﬃcacy/Tolerability. The primary outcome parameter
evaluated prior to and following the four week intervention
was the Pittsburg sleep quality index (PSQI). The study
included two secondary outcome parameters. The ﬁrst was
the World Health Organization quality of life questionnaire
in the Taiwan brief version (WHOQOL-BREF). Number
two, the menopause rating scale (MRS), consisting of 11
items, is rated on a ﬁve-point scale (0 = none, 4 = very
severe) that permits description on the perceived severity of
complaints such as hot ﬂashes, sweating, sleep disturbance,
and nervousness [12]. The questionnaire was developed to
gain further insights into each woman’s personal physio-
logical changes and the psychological impacts commonly
experienced by climacteric women [13]. The composite
scores for each of the dimensions (subscales) are based
on adding up the scores of the items of the respective
dimensions. The composite score (total score) is the sum
of the dimension scores. Useful categories for describing
clinical relevance of the index were: total score ≥16 (severe
complaints) and 1–15 (mild-to-moderate complaints).
The PSQI is a multidimensional, self-administered,
health status measure, which probes clinically important,
patient relevant symptoms in the areas of sleep quality
and quantity. The PSQI comprises 19-item questionnaires
with seven sub scales (subjective sleep quality, sleep latency,
sleep duration, habitual sleep disturbances, use of sleep
medication, and daytime dysfunction) [14]. Each subscale is
rated 0–3 with the higher scores reﬂecting more severe sleep
complaints. The sum of all the scores permits an analysis of
the patient’s overall sleep experience. The lower the overall
score, the better the person sleeps. The tool possesses ade-
quate internal reliability, validity, and consistency for clinical
and community samples of the climacteric population [15];
however,thequestionsareheavilybasedonmemoryoverthe
past month.
The Taiwan version of the WHOQOL-BREF comprises
four domains (i.e., physical, psychological, social, and envi-
ronmental) containing 24 facets, and two national items on
overall quality of life (QOL) and general health [16]. The
physical domain includes seven items (pain and discomfort,
energyandfatigue,sleepandrest,mobility, dailyliving activ-
ities, dependence on medication, and working capacity), six
in the psychological domain (positive feeling, thinking, and
concentration, self-esteem, bodily image and appearance,
negative feelings and spiritual/religious/personal beliefs),
three in the social domain (personal relationships, social
support, and sexual activity), and eight in the environmental
domain (physical safety and security, home environment,
ﬁnancial resources, availability of health and social care,
opportunities for acquiring new information and skills,
participationinrecreationandleisure,physicalenvironment,
and transport). Each item was scored on a Likert scale
rangingfrom1to5,withahigherscoreindicatingafavorable
condition. To standardize the domain scores for comparison,
the average score of each domain was calculated and then
multiplied by 4. Thus, the domain scores ranged from 4 to
20, with a higher score indicating a better quality of life in
the corresponding domain.
2.8. Safety Assessment. To set up active safety surveillance,
we ﬁrst surveyed the TM practitioners currently using SZRT
in the treatment of sleep diﬃculty to ascertain any AEs
these practitioners had noticed. They reported that such
medication occasionally resulted in gastrointestinal discom-
fort such as acid regurgitation, heartburn, and abdominal
discomfort when SZRT was administered orally at a dose of
4g, three times per day. We included these on our list for
surveillance.WealsoincludedonoursurveillancelisttheAEs
most frequently reported by the National Reporting System:
abdominal fullness, diarrhea, vomiting, nausea, urticaria,
itching, purpura, jaundice, skin vesicle (or local reddish
swelling), edema, hypotension, bradycardia, dyspnea, fever,
muscle cramp, and sleepiness. Other possible AEs were
enquired about as the 21st item. All subjects were required to
take objective laboratory tests to detect any abnormal liver,
blood, or kidney ﬁndings at the baseline and after four weeks
of SZRT therapy.
2.9. Statistical Analysis. Our analysis focused mainly on
changes in the seven-domain constructs of the PSQI
assessment along with the WHOQOL measures. The study
described the treatment eﬀects as changes in mean diﬀer-
encesamongtheparticipantsbetweenthebaselinescoresand
those measured at visits on weeks one and four. Separate
linear regression models were constructed for the response
variables of diﬀerentiated scores on subjective sleep quality,
sleep latency, sleep duration, habitual sleep disturbances, use
of sleep medication, and daytime dysfunction subscales, and
the WHOQOL-BREF domains. The explanatory variables in
the ﬁnal regression model were age, marital status, educa-
tional level, baseline severity of menopausal syndrome, and
BMI(inkg/m2).Toexamineimprovementacrossthemonth,
two indicator variables for visits at weeks one and four were
also included in the regression model. The coeﬃcients of
the two indicator variables represent the diﬀerences between
the average value of measured scores for the visits at weeks
one and four versus those at the baseline. We assumed
correlatederrortermsamongtherepeatedmeasurementsfor
eachparticipant.Finally,eachsinglePSQIscoreitemwasalso
examined separately to identify any PSQI items sensitive to
treatmentbySZRT. All of the above analyses were performed
using the SAS (9.2 edition) software package.
3. Results
3.1. Study Population. Of the 99 sample patients, 32 were
deemedtobeineligible.Theprincipalreasonsforineligibility
were a disinterest in participation (n = 16), medical condi-
tions and medications (n = 3), did not show up for further4 Evidence-Based Complementary and Alternative Medicine
Table 2: Baseline demographic and clinical characteristics for the 67 participants.
Variables MRS < 16 (n = 34) MRS ≥ 16 (n = 33) Odds ratio†
mean (SD) mean (SD)
Demographics
Age (year) 55.9 (6.8) 52.4 (6.0) 1.260∗
Height (cm) 157.4 (6.7) 156.6 (4.7) 1.018
Weight (kg) 54.4 (7.3) 57.5 (11.0) 1.169
BMI (kg2/cm2) 22.6 (2.7) 23.4 (4.1) 0.551
Serum hormonal level
FSH (mIU/mL) 50.4 (25.7) 51.9 (27.2) 0.948
LH (mIU/mL) 30.1 (16.1) 28.5 (13.8) 1.052
Endpoint (scores)
PSQI 12.4 (3.3) 13.7 (2.1) 0.581
Subjective sleep quality 2.3 (0.5) 2.5 (0.5) 4.171
Sleep latency 2.4 (0.8) 2.4 (0.7) 2.652
Sleep duration 2.2 (0.8) 2.6 (0.6) 0.218∗
Habitual sleep eﬃciency 1.7 (1.2) 2.0 (1.0) 1.559
Sleep disturbances 1.4 (0.6) 1.8 (0.6) 1.099
Daytime dysfunction 1.4 (0.9) 1.6 (1.0) 1.973
Domains of WHOQOL-BREF
Physical 13.0 (2.1) 11.6 (1.7) 1.493
Psychological 12.3 (2.1) 10.4 (2.1) 2.185∗
Social 13.3 (2.1) 12.5 (1.8) 0.818
Environmental 14.1 (1.8) 12.9 (2.2) 0.702
Abbreviation: BMI: body mass index; FSH: follicular stimulating hormone; LH: luteinizing hormone; MRS: the menopause rating scale; PSQI: the Pittsburg
sleep quality index; WHOQOL-BREF: the World Health Organization’s quality of life instrument—Short Version.
†Odds ratio are calculated for the comparison of diﬀerence between MRS < 16 and MRS ≥ 16 groups by logistic regression.
∗P<. 05
study (n = 11), and no evidence of severe sleep diﬃculty
(n = 2). In all, 61 (91%) of the initial 67 participants
intending to treat (ITT) completed the 4-week study without
anymajorprotocolviolation.Thesewereincludedintheper-
protocol data set for safety and eﬃcacy analyses. Reasons
for the six6 withdrawals were AEs (n = 3), lack of eﬃcacy
(n = 1), and prior treatment of other disease (n = 2).
Table 2 summarizes the baseline demographics and clin-
ical characteristics of the study. The women in the study
exhibited a mean age of 55, normal BMI, 73% married,
a n d3 9 %h a da ne d u c a t i o nl e v e lo fj u n i o rh i g ho rb e l o w .
To further separate out the confounding factors of multiple
menopausalsymptomsinﬂuencingtheoutcomeofthestudy,
participants were ﬁltered into two groups consisting of mild-
to-moderate menopausal symptoms (MRS < 16) versus
severe menopausal symptoms (MRS ≥ 16), based on their
baseline MRS score.
3.2.SafetyandAdverseEﬀects. Alltestedbiomarkersafterthe
4-week SZRT intervention did not demonstrate signiﬁcant
changes. However, the study raised notable safety issues.
Three participants withdrew from the study due to AEs.
Intolerable side eﬀectsresultinginwithdrawalincludedthree
events of stomachache, diarrhea, and dizziness. We carried
out periodic evaluation of any unexpected symptoms during
the treatment period and found that the perception of gas-
trointestinal discomfort after SZRT consumption two days
later and dramatically relieved after SZRT discontinuance.
We were unable to rule out the possibility that consuming
SZRT will cause the deterioration of gastrointestinal and/or
neurologic symptoms preexisted during climacteric period.
3.3. Eﬃcacy. After four weeks of treatment, there were signi-
ﬁcant improvements in each of the PSQI subscales. The
magnitudes of the improvements in the PSQI subscales were
37.5% forsubjective sleep quality, 25% forsleep latency, 25%
forsleepduration,38.9%forhabitualsleepdisturbances,and
40%fordaytimedysfunction(Table 3).Themeanamountof
timetofallasleepperdayreducedfrom53.6±46.0minutesat
thebaselineto31.0±20.0minutesattheendofthestudy.The
mean sleep duration per day prolonged from 4.7 ±1.0h o u r s
at the baseline to 5.5 ± 1.1 hours after 4-week treatment.
Among those intended to treat, 10 out of 67 women
increased their MRS domain scores at the end of the study.
Two of these women reported sleep quality at the same
status as their baseline, one of these women reported sleep
quality worse than her baseline, the remaining seven women
perceived better sleep quality by week four.
The results of the multiple linear regression analyses
indicate the eﬀects of the diﬀerent determinants on the
outcome scores of the PSQI subscales. After controlling for
the degree of severity of menopausal symptoms and otherEvidence-Based Complementary and Alternative Medicine 5
Table 3:Majorvariablesofthemeasurementsbetweenweeks1and4andbaselinearesummarizedasmeandiﬀerencewitha95%conﬁdence
interval.
Variable deﬁnition Baseline Week 1 Paired T-Test Week 4 Paired T-Test
mean (SD) mean (SD) mean diﬀerence (95% CI) mean (SD) mean diﬀerence (95% CI)
Pittsburg sleep quality index 13.0 (2.9) 11.0 (3.4) (−2.86, −1.26)∗∗∗ 9.0 (3.2) (−4.93, −3.10)∗∗∗
Subjective sleep quality 2.4 (0.5) 1.9 (0.6) (−0.62, −0.27)∗∗∗ 1.5 (0.7) (−1.10, −0.69)∗∗∗
Sleep latency 2.4 (0.8) 2.1 (0.9) (−0.44, −0.04)∗ 1.8 (1.0) (−0.86, −0.36)∗∗∗
Sleep duration 2.4 (0.8) 2.1 (0.8) (−0.44, −0.07)∗∗ 1.8 (0.8) (−0.77, −0.36)∗∗∗
Habitual sleep eﬃciency 1.8 (1.1) 1.4 (1.1) (−0.67, −0.16)∗∗ 1.1 (1.1) (−1.04, −0.49)∗∗∗
Sleep disturbances 1.6 (0.6) 1.6 (1.3) (−0.27, 0.39) 1.4 (0.6) (−0.39, −0.03)∗
Daytime dysfunction 1.5 (1.0) 1.1 (0.9) (−0.67, −0.22)∗∗∗ 0.9 (0.8) (−0.88, −0.34)∗∗∗
WHOQOL-BREF Scores
Physiological domain 12.3 (2.0) 13.0 (1.9) (0.29, 1.05)∗∗∗ 13.5 (2.3) (0.64, 1.63)∗∗∗
Psychological domain 11.4 (2.3) 11.7 (2.6) (0.00, 0.78) 11.9 (2.6) (0.02, 0.96)∗
Social domain 12.9 (2.0) 13.0 (2.1) (−0.36, 0.48) 12.8 (2.5) (−0.70, 0.43)
Environment domain 13.5 (2.1) 13.6 (2.2) (−0.22, 0.42) 13.6 (2.5) (−0.42, 0.59)
FSH (mIU/mL) 51.2 (26.2) — — 51.9 (28.5) (−4.40, 4.29)
LH (mIU/mL) 29.3 (14.9) — — 30.3 (15.9) (−1.32, 3.31)
Abbreviation: WHOQOL-BREF: the World Health Organization’s quality of life instrument—short version; CI: conﬁdence interval; FSH: follicle-stimulating
hormone; LH: luteinizing hormone.
∗P<. 05 by paired t-test compared with baseline; ∗∗P<. 01 by paired t-test compared with baseline; ∗∗∗P<. 001 by paired t-test compared with baseline.
determinants had been controlled, the model constructions
demonstrated signiﬁcant improvements in the subjective
sleep quality, sleep latency, sleep duration, sleep eﬃciency,
sleep disturbances, and daytime dysfuction after 4-week
treatment. In addition, the present data demonstrated that
SZRT produced a superior beneﬁt of daytime function in
women with severe menopausal symptoms compared towith
women with mild menopausal symptoms. However, there
were no signiﬁcant improvements in the domain scores of
the WHOQOL-BREF after controlling for other potential
confounders.
4. Discussion
To the best of our knowledge, this study is the ﬁrst of its
kind to investigate the potential eﬃcacy and safety of SZRT
in improving quality of sleep among climacteric women
with sleep diﬃculty, as measured by PSQI. Our results
demonstrate a signiﬁcant improvement of sleep quality in
climacteric women after four weeks of SZRT treatment.
Although we used self-comparison to rule out potential
confounding by BMI, smoking, exercise, and socioeconomic
status, the possibility of a placebo eﬀect might still exist.
Thus, we further analyzed the improvement in subjective
sleep quality, sleep latency, sleep disturbance, sleep duration,
sleep eﬃciency, daytime dysfunction, and total PSQI scores
by stratifying data into two groups with diﬀerent degrees
of severity of menopausal symptoms. A similar severity
pattern in sleep diﬃculty and total PSQI scores were found
at the baseline examination for these two groups (Table 2).
Pronouncedimprovementofdaytimedysfunctionwasfound
in the severe group after four weeks of SZRT treatment.
In the mild-to-moderate group, the mean total PSQI
scores improved on average 3.6 points by the end of the
study, and 73.5% of the participants perceived the improve-
ment of sleep quality after four-weeks of SZRT treatment.
8.8% of the women with mild-to-moderate menopausal
symptoms experienced deteriorated sleep quality over the
study period, whereas 81.8% of the women with severe
menopausal symptoms perceived the improvement of sleep
quality at the end of the study. Nearly 12.1% of the women
perceived poorer sleep quality after four weeks of SZRT
treatment. Although head-to-head comparisons were not
available, our results suggest that subjective sleep quality
and daytime dysfunction of climacteric women with mild
menopausal symptoms did not worsen during the treatment
period. Although this study did not use a placebo group
or randomization, the signiﬁcant diﬀerence in improved
score of daytime dysfunction indicated a positive eﬀect
of SZRT treatment in climacteric women who perceived
poor sleep and severe menopausal symptoms (Table 4). This
ﬁnding was similar to the ﬁndings of a prior study [17],
in which sleep-related diﬃculty with daytime functioning
signiﬁcantly improved after a 4-week zolpidem treatment
among women with menopause-related insomnia.
The present data showed that there was no eﬀect after
one-week SZRT treatment and was signiﬁcant improvement
for sleep quality after four-week treatment at a dose of 4.0g
thrice daily. From a physiologically based pharmacokinetic
point of view, it takes more than one week to demonstrate
the symptom-relief eﬀect of the active ingredients in SZRT,
which appears to resemble a slow-acting drug, and may
not be appropriate to compare its action head-to-head with
conventional medications of rapid action, such as zolpidem
[17]. In the outcome evaluation study provides us precious
evidence to avoid direct comparison of formula SZRT with
rapid action medications in future randomized controlled
trials.6 Evidence-Based Complementary and Alternative Medicine
Table 4: The estimates of regression coeﬃcients and standard errors for modeling outcomes of Pittsburg sleep quality index subscales.
Variable deﬁnitions
PSQI subscales†
Subjective sleep
quality Sleep latency Sleep duration Habitual sleep
eﬃciency
Sleep
disturbances
Daytime
dysfuction
Coeﬀ SE Coeﬀ SE Coeﬀ SE Coeﬀ SE Coeﬀ SE Coeﬀ SE
MRS at baseline
(<16 versus ≥16)‡ −0.086 0.158 0.126 0.222 −0.233 0.193 −0.259 0.236 0.179 0.141 0.592∗ 0.237
Sleep quality at
baseline
(poor versus very
poor)§
−0.579∗∗ 0.177 0.239 0.248 0.293 0.217 0.108 0.264 0.094 0.158 −0.171 0.266
Mean score
improvement at
week 1 versus
baseline
0.020 0.030 −0.060 0.042 0.030 0.037 0.049 0.045 −0.020 0.027 −0.063 0.045
Mean score
improvement at
week 4 versus
baseline
−0.129∗∗∗ 0.031 −0.106∗ 0.044 −0.159∗∗∗ 0.038 −0.217∗∗∗ 0.047 −0.121∗∗∗ 0.028 −0.120∗ 0.047
Body Mass Index
(<25 versus ≥25) 0.089 0.189 −0.224 0.266 0.385 0.232 0.528 0.283 −0.401∗ 0.170 −0.381 0.284
Marital status
(married versus
others)
−0.027 0.170 0.397 0.239 −0.108 0.209 −0.221 0.254 −0.168 0.153 0.090 0.256
Educational level
(college or above
versus others)
0.004 0.175 0.191 0.246 −0.114 0.215 −0.026 0.262 −0.006 0.157 0.053 0.263
Age 0.002 0.014 0.022 0.020 −0.025 0.017 −0.007 0.021 0.013 0.013 0.021 0.021
†PSQI: the Pittsburg sleep quality index.
‡MRS: the menopause rating scale.
§Sleep quality is an item of the Pittsburg sleep quality index on a 4-point scale: 0 is very good sleep quality; 1 is fairly good sleep quality; 2 is fairly bad sleep
quality; 3 indicates very bad sleep quality.
∗indicates P<. 05; ∗∗indicates P<. 01; ∗∗∗indicates P<. 001.
Following the recommendations of the World Health
Organization, we used the WHOQOL-BREF, a multidimen-
sional measure of QOL, as one secondary outcome in this
study [18]. However, there were no statistically signiﬁcant
changes in the scores of either the WHOQOL domains or
the diﬀerent facets for those climacteric women suﬀering
from sleep diﬃculty who showed signiﬁcant improvements
in sleep quality after treatment (Table 5). A major reason for
this result is that the mean scores of the WHOQOL-BREF at
the baseline were comparatively high. Consequently, it may
be unrealistic to expect a further marked increase in such
scores. Another explanation was that because of its generic
nature, the WHOQOL-BREF domain scores are not sensitive
or responsive enough to detect changes.
Clinical trials have never explored the SZRT dosage used
in this study (4.0g thrice daily). Without the present data,
TM practitioners in Japan, South Korea, China, and Taiwan
will continue to prescribe SZRT to patients in their everyday
practice based on documentations from a thousand years
ago. The results of this study provide (about IIb level [18])
that three participants had to withdraw from the study due
to AEs, and that the three leading adverse drug reactions
included stomachache, diarrhea, and dizziness. The AEs
discovered by this study, though not serious enough to
prohibit the use of this formula clinically, show that TM
practitioners must be alert to the possibility that prescribing
SZRT can cause severe gastrointestinal adverse eﬀects or
dizziness. Further research to clarify the safety of SZRT’s use
is necessary.
The present study recruited only climacteric women with
poor sleepandusedself-comparisontoruleoutthepotential
confoundersofBMI,age,exercise,andsocioeconomicstatus.
This type of study presents particular advantages. Limited
subject numbers create simple and comprehensive data
analysis that can be used to identify possible trends, with
which a larger sample size could prove to be signiﬁcant.
Participants do not have to spend the extended amount of
timenecessaryforacrossoverdesign,analternatemethodfor
dealing with a limited number of subjects. Additionally, this
type of study avoids the ethical dilemma regarding giving a
placebo to symptomatic participants who could be receiving
valid treatment.
Amajorlimitationofourstudyisitsobservationalnature
or lack of a randomized placebo group. Therefore, our claim
of an eﬃcacy associated with SZRT might not be as strict as
that from a RCT. No matter how popular the use of SZRTEvidence-Based Complementary and Alternative Medicine 7
Table 5: The estimates of regression coeﬃcients and standard errors for modeling outcomes of WHOQOL-BREF Scores.
Variable deﬁnitions
WHOQOL-BREF scores†
Physical Psychological Social Environmental
Coeﬀ SE Coeﬀ SE Coeﬀ SE Coeﬀ SE
MRS at baseline
(<16 versus ≥16)‡ 0.217 0.463 0.336 0.523 0.186 0.600 0.625 0.545
Sleep quality at baseline
(poor versus very poor)§ 0.673 0.519 0.101 0.586 0.420 0.672 0.061 0.610
Improvement at week 1
compared with baseline 0.137 0.088 0.046 0.099 0.051 0.113 0.062 0.103
Improvement at week 4
compared with baseline 0.157 0.092 0.070 0.104 0.012 0.119 0.075 0.108
Body mass index
(<25 versus ≥25) 0.082 0.556 −0.008 0.628 0.597 0.720 −0.321 0.654
Marital status
(married versus others) 0.136 0.500 0.705 0.565 1.335 0.647∗ 0.625 0.588
Educational level
(college or above versus
others)
−0.458 0.515 −0.121 0.582 −0.298 0.666 −0.716 0.605
Age 0.013 0.042 0.023 0.047 −0.040 0.054 0.011 0.049
†WHOQOL-BREF: the World Health Organization’s quality of life instrument—short version.
‡MRS: the menopause rating scale.
§Sleep quality is an item of the Pittsburg sleep quality index on a 4-point scale: 0 is very good sleep quality; 1 is fairly good sleep quality; 2 is fairly bad sleep
quality; 3 indicates very bad sleep quality.
∗indicates P<. 05; ∗∗indicates P<. 01; ∗∗∗indicates P<. 001.
is in the markets of China, Japan, South Korea, and Taiwan,
no RCT has been conducted yet. The evidence we obtained
from the present study can provide precious data on safety
proﬁles of SZRT and direct evaluation of its eﬀectiveness,
meanwhile this study can serve as prior information for the
design of RCTs. Another limitation of this study is that since
participants were all climacteric women with sleep problems
in Taiwan, there needs to be caution in generalizing these
ﬁndings to cover patients in other nations.
5. Conclusion
Excluding women with a past history of stomachache,
diarrhea, and dizziness, the dosage form and prescription
pattern of the SZRT preparation appears to be a well-
tolerated and valuable, short-term alternative therapeutic
option for improving daytime dysfunction in women with
poor sleep quality during their climacteric period. Placebo
eﬀect, natural ﬂuctuation, insuﬃcient followup time, and/or
other unobserved factors could confound the results of
the current study. A prospective randomized, double-blind,
controlled trial to further evaluate the eﬃcacy of SZRT
on climacteric women with sleep diﬃculty is warranted in
future studies.
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